Evidence map›Paper›PMID 35347453›Full record

ArticleJournal of neurology2022

Validity of cingulate-precuneus-temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer's Disease.

Valeria Isella, Cinzia Crivellaro, Anna Formenti, Monica Musarra, Sara Pacella, Sabrina Morzenti, Francesca Ferri, Cristina Mapelli, Francesca Gallivanone, Luca Guerra and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Valeria IsellaNeurology Department, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy. valeria.isella@unimib.it.ORCID http://orcid.org/0000-0003-1850-1236
Cinzia CrivellaroNuclear Medicine Unit, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy.
Anna FormentiNeurology Department, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy.
Monica MusarraNuclear Medicine Unit, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy.
Sara PacellaNuclear Medicine Unit, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy.
Sabrina MorzentiMedical Physics, San Gerardo Hospital, Monza, Italy.
Francesca FerriNeurology Department, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy.
Cristina MapelliNeurology Department, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy.
Francesca GallivanoneInstitute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Segrate, Milan, Italy.
Luca GuerraNuclear Medicine Unit, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy.
Ildebrando AppollonioNeurology Department, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy.
Carlo FerrareseNeurology Department, San Gerardo Hospital, University of Milano - Bicocca, Monza, Italy.
University of Milano-Bicocca · ITAzienda Ospedaliera San Gerardo · ITInstitute of Molecular Bioimaging and Physiology · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia or MCI due to Alzheimer's Disease (AD), permits to distinguish amyloid-positive from amyloid-negative patients with non-classical AD phenotypes at the single-case level. We enrolled 127 neurodegenerative patients with cognitive impairment and a positive (n. 63) or negative (n. 64) amyloid marker (cerebrospinal fluid or amy-PET). Three rating methods of FDG-PET scan were applied: purely qualitative visual interpretation of uptake images (VIUI), and visual reading assisted by a semi-automated and semi-quantitative tool: INLAB, provided by the Italian National Research Council, or Cortex ID Suite, marketed by GE Healthcare. Fourteen scans (11.0%) patients remained unclassified by VIUI or INLAB procedures, therefore, validity values were computed on the remaining 113 cases. The three rating approaches showed good total accuracy (77-78%), good to optimal sensitivity (81-93%), but poorer specificity (62-75%). VIUI showed the highest sensitivity and the lowest specificity, and also the highest proportion of unclassified cases. Cases with asymmetric temporo-parietal hypometabolism and a progressive aphasia or corticobasal clinical profile, in particular, tended to be rated as AD-like, even if biomarkers indicated non-amyloid pathology. Our findings provide formal support to the value of PCTP hypometabolism for single-level diagnosis of amyloid pathophysiology in atypical AD, but also highlight the risk of qualitative assessment to misclassify patients with non-AD PPA or CBS underpinned by asymmetric temporo-parietal hypometabolism.

Indexed as

Alzheimer DiseaseAmyloidosisCognitive DysfunctionBiomarkersBrainFluorodeoxyglucose F18HumansParietal LobePositron-Emission TomographyBiomarkersFluorodeoxyglucose F18Alzheimer’s DiseaseBiomarkersBrain metabolismDementiaFDG-PET

Identifiers

PMID35347453
PMCPMC9293827
OpenAlexW4220878028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.